Hemostemix (CVE:HEM) Sets New 12-Month Low – Here’s Why

Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week low on Wednesday. The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 680,800 shares. The stock had previously closed at C$0.04.

Hemostemix Stock Down 14.3%

The stock’s 50-day moving average is C$0.06 and its 200-day moving average is C$0.07. The company has a market cap of C$6.34 million, a price-to-earnings ratio of -1.15 and a beta of -0.14. The company has a current ratio of 0.13, a quick ratio of 0.48 and a debt-to-equity ratio of -61.85.

Hemostemix Company Profile

(Get Free Report)

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Recommended Stories

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.